Jefferies Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $77
Jefferies analyst Akash Tewari maintains $Ionis Pharmaceuticals(IONS.US)$ with a buy rating, and maintains the target price at $77.According to TipRanks data, the analyst has a success rate of 58.0%
Analysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX), MoonLake Immunotherapeutics (MLTX) and Ionis Pharmaceuticals (IONS)
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Leerink Partners Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Announces Target Price $56
Leerink Partners analyst Mani Foroohar maintains $Ionis Pharmaceuticals(IONS.US)$ with a buy rating, and sets the target price at $56.According to TipRanks data, the analyst has a success rate of 40.1
Ionis Pharmaceuticals: A Buy Rating With a Lowered Price Target Amidst Strong Growth Prospects
Ionis Pharmaceuticals Down Over 10%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk